
Sign up to save your podcasts
Or
Dr. Anna Wolska sits down with experts, Dr. Michelle Petri and Dr. Nick Ballew, analyzing the effectiveness of SLE treatments Belimumab and Anifrolumab. The conversation delves into their meticulous study, where they examined the 52-week SLE Responder Index (SRI)-4 responses, providing crucial data for informed lupus patient care. The study data, based on rigorous randomized trials and systematic literature reviews, offers clinicians invaluable insights into treatment decisions for people living with lupus.
Read the published article: http://dx.doi.org/10.1136/lupus-2023-000907
3.9
1414 ratings
Dr. Anna Wolska sits down with experts, Dr. Michelle Petri and Dr. Nick Ballew, analyzing the effectiveness of SLE treatments Belimumab and Anifrolumab. The conversation delves into their meticulous study, where they examined the 52-week SLE Responder Index (SRI)-4 responses, providing crucial data for informed lupus patient care. The study data, based on rigorous randomized trials and systematic literature reviews, offers clinicians invaluable insights into treatment decisions for people living with lupus.
Read the published article: http://dx.doi.org/10.1136/lupus-2023-000907
38 Listeners
5 Listeners
51 Listeners
8 Listeners
5 Listeners
3 Listeners
2 Listeners
4 Listeners
9 Listeners
38 Listeners
14 Listeners
1 Listeners
51 Listeners
0 Listeners
6 Listeners
11,860 Listeners
501 Listeners
123 Listeners
3 Listeners
112,284 Listeners
3 Listeners
25 Listeners
368,395 Listeners
24 Listeners
47,940 Listeners
68 Listeners
33 Listeners
29,131 Listeners
4 Listeners
45 Listeners
20,121 Listeners
2 Listeners
2 Listeners
0 Listeners